Long-term data from the phase 3 EF-14 study showed that Optune plus temozolomide had a survival benefit compared to temozolomide alone.
Kathy Boltz, PhD
Advertisement
Articles by Kathy Boltz, PhD
Advertisement
Latest Updated Articles
Long-Term Data Show Optune Offers a Survival Benefit in GlioblastomaPublished: November 21st 2016 | Updated:
Advertisement
Advertisement
Trending on CURE
1
SUNRiSE-1 Participant Shares Insights on Bladder Cancer Education
2
Fertility Preservation During Breast Cancer: ‘I Would Do It All Again’
3
What Are My Options for Liver Cancer Treatment?
4
Becoming Cancer-Aware: How My Diagnosis Changed the Way My Family Sees Everyday Products
5
